Navigation Links
China PharmaHub Corp. Enters Into Definitive Agreement for Humanized Antibody

BOSTON, July 1 /PRNewswire/ -- China PharmaHub Corp. ("PharmaHub"), announced today that it has entered into a definitive agreement with Dr. David Weaver and Dr. Michael Rynkiewicz.  In addition, PharmaHub contemplates merging with World Wide Relics, Inc. (OTC Bulletin Board: WRLC) of which it recently purchased a 77% interest.  

The management of World Wide Relics ("WWR") and PharmaHub are looking forward to the potential merger and are working diligently towards it.  PharmaHub is engaged in the business of licensing, development and commercialization of pharmaceutical and healthcare products and technologies between Chinese pharmaceutical companies and other pharmaceutical companies located worldwide, with initial emphasis in the United States and Europe. For existing WWR shareholders, the merger could add substantial value due to PharmaHub's existing business relationships and agreements.  

Pursuant to PharmaHub's agreement with Dr. Weaver and Dr. Rynkiewicz, a joint venture has been created and will be known as Akanas Therapeutics, Inc. ("Akanas"), of which PharmaHub owns a 35% interest.  The joint venture will have the exclusive rights to the intellectual property, which includes patents on a proprietary technology using atomic structure for antibody humanization to rapidly and cost-effectively create humanized antibodies which retain high affinity and avoid immunogenicity.  Dr. Weaver and Dr. Rynkiewicz invented the core Akanas platform technology in 2005.  Dr. Weaver has over 15 years of experience in the research and development of cancer biology and immunology. He received postgraduate training at MIT and the Whitehead Institute, and a Ph.D. in Biological Chemistry from Harvard. Dr. Rynkiewicz is an experienced protein crystallographer with training from Boston University and University of Pennsylvania. He received a Ph.D. in Chemistry from Boston University and a B.S. in Chemistry at MIT.  PharmaHub will work with Akanas to expand its existing research, development, commercialization and marketing on a worldwide basis.  

"We're excited to enter into this agreement," stated Richard Lui, Chief Executive Officer of PharmaHub.  "This marks another of PharmaHub's endeavors where we will be utilizing our resources both in the U.S. and in China to strive to bring these innovative technologies to patients around the world.  Akanas' humanized therapeutic antibodies technology has already produced several compositions which Management believes showed superiority in preclinical trials over existing antibodies on the market.  We look to provide a meaningful impact to the disease markets by having improved activity and reduced side effects as we continue to carry out preclinical and clinical trials in China.  This agreement demonstrates the collaborative effort that PharmaHub is striving for with each scientist or company with whom we work."

Lui continued, "Akanas' humanized antibody can potentially be used to treat such diseases as cancer and rheumatoid arthritis.  With the market for disease treatment in China and the U.S. booming, and the global antibody drug market expected to generate $30 billion in worldwide sales in 2009, with an annual growth rate of 14 percent through 2012, according to Datamonitor, Management believes that the potential for China PharmaHub is enormous."

About PharmaHub:

China PharmaHub Corp. is engaged in the business of licensing, developing and the commercialization of pharmaceutical and healthcare products and technologies between Chinese pharmaceutical companies and other pharmaceutical companies located worldwide, with initial emphasis in the United States and Europe. Management believes that PharmaHub brings a unique wealth of resources to assist scientists and companies in bringing their ideas to reality.  PharmaHub's corporate headquarters are located in California, with offices in Boston and China.

About World Wide Relics:

World Wide Relics, Inc. produces and markets historical costumes and reenactment clothing lines. The company sells its products to the enthusiasts and collectors on e-stores, such as World Wide Relics, Inc. was founded in 2005 and is based in New York, New York.

Forward-Looking Statements

This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Except as otherwise required by the federal securities laws, the Company disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein.

SOURCE China PharmaHub Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco
2. Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair
3. China BCT Signs Exclusive Distribution Contract With Liujiang County Chinese Medicine Hospital
4. China Medical Technologies Announces the Recent Publication of a Study on its SPR Analyzer and HPV DNA Chip in Cancer Genetics and Cytogenetics and the Creation of a Medical Publications Column to the Investor Relations Section on its Website
5. VacChina 2010 - A Premium Event to Define the Vaccine Industry in Asia
6. Kun Run Biotechnology Announces That They Have Obtained the Manufacturing Approval for Entecavir from the China State Food and Drug Administration
7. Diagnostic Imaging Markets in Brazil, Russia, India, China (BRIC) 2010 - 2015: MarketsandMarkets
8. Emerging Markets (BRIC - Brazil, Russia, India and China): Patient Monitors 2010 - 2014
9. China Medical Technologies Reports Financial Results for Fourth Fiscal Quarter and Full Year ended March 31, 2010
10. China Sky One Medicals Subsidiaries Recognized as Provincial Model Companies
11. Reportlinker Adds China Patient Monitoring Market Outlook to 2016
Post Your Comments:
(Date:11/26/2015)... 2015 Research and Markets ( ) has ... Market Outlook to 2019 - Rise in Cardiac Disorders and ... report to their offering. Boston ... scientific and others. --> The ... Boston scientific and others. ...
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Japanese Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... convenient way to dispense prescription medications at home, so he invented the patent-pending ... monitor and dispense prescription medications. In doing so, it could help to prevent ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... online platform for mental health and wellness consultation, has collaborated with a leading ... bridge the knowledge gap experienced by parents and bring advice from parenting experts ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
Breaking Medicine News(10 mins):